Healthcare utilization and associated costs following initiation of perampanel in patients with epilepsy


      • Perampanel has a unique mechanism of action which blocks glutamate activity at postsynaptic AMPA receptors.
      • In controlled trials and meta-analyses perampanel has been shown to reduce the frequency of seizures in patients with epilepsy.
      • We considered the association of perampanel with resource use in a before-after comparison and compared with controls.
      • Following initiation with perampanel, patients had fewer inpatient and accident and emergency contacts.
      • Overall annualized healthcare costs were reduced following initiation with perampanel, offering potential for cost saving.



      We compared health service utilization and costs for patients with epilepsy before and after initiation of perampanel and compared with matched controls.


      Patients were selected from the Clinical Practice Research Datalink (CPRD). Patients initiating perampanel were matched to controls initiating an alternate add-on therapy for the same underlying epilepsy subtype. First prescription defined index date. Primary and secondary care contacts and associated costs were aggregated in the 12 months before and after index date. Secondary care contacts were available for a subset (~60%) of patients.


      Three hundred and forty-three patients treated with perampanel were identified. One hundred and eighty-three (53.4%) were male, mean age was 39.1 (sd: 16.0). Mean epilepsy duration was 21.1 (standard deviation (sd): 13.3) years. Two hundred and eighty-seven (83.7%) were matched to controls. Inpatient admissions with a primary diagnosis of epilepsy (0.5 versus 0.2 per patient-year (ppy), p = 0.002) and neurology specific outpatient appointments (3.2 versus 2.9 ppy, p = 0.041) were significantly reduced following initiation with perampanel. Total costs attributable to epilepsy (£1889 to 1477 ppy) and overall secondary costs (£2593 to £2102) were also significantly reduced. There was no significant difference in primary care, outpatient, or general inpatient admissions. Compared with controls, there was a significant reduction in primary epilepsy admissions (incidence rate ratio (IRR): 0.423; 95% Confidence intervals (CI): 0.198–0.835) but a significant increase in outpatient appointments (1.306; 95% CI: 1.154–1.478) and accident and emergency contacts (1.603; 95% CI: 1.081–2.390) for patients treated with perampanel.


      Treatment with perampanel is associated with reduced epilepsy-related inpatient admissions and accident and emergency contacts.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Epilepsy & Behavior
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chang B.S.
        • Lowenstein D.H.
        Mechanisms of disease: epilepsy.
        N Engl J Med. 2003; 349: 1257-1266
        • World Health Organization
        Epilepsy fact sheet.
        • National Institute for Health and Care Excellence
        Epilepsies: diagnosis and management.
        Date: 2012
        Date accessed: March 2, 2018
        • Electronic Medicines Compendium
        SPC Fycompa 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg film-coated tablets.
        Date: 2018
        Date accessed: March 2, 2018
        • Committee for Medicinal Products for Human Use (CHMP)
        Summary of opinion (post authorisation): fycompa perampanel.
        • Hsu W.W.Q.
        • Sing C.W.
        • He Y.
        • Worsley A.J.
        • Wong I.C.
        • Chan E.W.
        Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy.
        CNS Drugs. 2013; 27: 817-827
        • French J.A.
        • Krauss G.L.
        • Biton V.
        • Squillacote D.
        • Yang H.
        • Laurenza A.
        • et al.
        Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.
        Neurology. 2012; 79: 589-596
        • French J.A.
        • Krauss G.L.
        • Steinhoff B.J.
        • Squillacote D.
        • Yang H.
        • Kumar D.
        • et al.
        Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
        Epilepsia. 2013; 54: 117-125
        • French J.A.
        • Krauss G.L.
        • Wechsler R.T.
        • Wang X.F.
        • Di Ventura B.
        • Brandt C.
        • et al.
        Perampanel for tonic–clonic seizures in idiopathic generalized epilepsy.
        Neurology. 2015; 85: 950-957
        • Gao L.
        • Xia L.
        • Zhao F.L.
        • Li S.C.
        Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials.
        Epilepsy Res. 2013; 103: 31-44
        • Rohracher A.
        • Zimmermann G.
        • Villanueva V.
        • Garamendi I.
        • Sander J.W.
        • Wehner T.
        • et al.
        Perampanel in routine clinical use across Europe: pooled, multicenter, observational data.
        Epilepsia. 2018; 59: 1727-1739
        • Curtis L.
        • Burns A.
        Unit costs of health & social care.
        • Health and Social Care Information Centre
        HRG4 2014/15 payment grouper. 2014.
        ( (accessed 2 March 2018))
        • Monitor, NHS England
        National Tariff Payment System 2014–15.
        • Villanueva V.
        • Garcés M.
        • López-González F.J.
        • Rodriguez-Osorio X.
        • Toledo M.
        • Salas-Puig J.
        • et al.
        Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study.
        Epilepsy Res. 2016; 126: 201-210
        • Faught E.
        • Laliberte F.
        • Wang Z.
        • Barghout V.
        • Haider B.
        • Lejeune D.
        • et al.
        Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.
        Epilepsia. 2017; 58: 1742-1748
        • Trinka E.
        • Steinhoff B.J.
        • Nikanorova M.
        • Brodie M.J.
        Perampanel for focal epilepsy: insights from early clinical experience.
        Acta Neurol Scand. 2016; 133: 160-172